Trial Profile
An open-label, multicenter, phase II study of AT-101 in combination with rituximab in patients with untreated, grade I-II, follicular non-Hodgkin's lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2010
Price :
$35
*
At a glance
- Drugs AT 101 (Primary) ; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Ascenta Therapeutics
- 04 Dec 2008 Planned end date changed from 1 Aug 2008 to 1 Nov 2008, according to ClinicalTrials.gov.
- 04 Dec 2008 Status changed from active, no longer recruiting to completed,according to ClinicalTrials.gov.
- 03 May 2008 Status changed from recruiting to in progress.